Banking

Good morning traders we hope you're ready for the first trading week of November to start and had an opportunity to hopefully recover from any storm damages that may have occurred, the team at HOT STOXX has been scanning the markets and there are a few stocks that we feel may potentially breakout this week. Take a look at this below:

** ON RADAR **

Ticker: VNTH

VANTAGE HEALTH INC.

Risk Level: Medium

Volatility Level: Medium High

Liquidity Level: High

Make sure VNTH is on your watch list for Tuesday’s trading day!

It looks like something interesting is happening with Vantage Health (OTCBB: VNTH). Over the last 40 days some very interesting trading patterns have developed. On 9/26 and on 10/23 VNTH had two large block trades on each of those days which crossed the market and then all was quiet until this past Friday11/2/12) when it traded 276,600 shares. The difference is that Friday’s trades were clearly retail buying and the stock closed up 102% for the day.

Exactly one year ago VNTH traded at $0.165 and on July 14, 2011 VNTH traded at a high of $0.50. With only 80 Million shares issued and outstanding (60 Million restricted shares are owned by the Company’s President) and approximately 17 Million free trading shares VNTH can quickly break out to the $0.25 level very quickly.

VNTH is clearly on a bullish trend, one you cannot ignore and one you should bank on immediately.

The following are the reasons why you need to buy VNTH:

• Vantage Health (VNTH) is a Nevada Corporation with its operating subsidiary based in Cape Town, South Africa. Vantage Health is an importer and distributor of pharmaceutical products and medical consumables to the public and private sectors. Vantage Health's business model is structured around its localized partnerships in sub-Saharan Africa, on a country-by-country basis. This model is designed to roll out quickly across various African nations using the same partnership principles and approach.

• Moxisign (Vantage Health 100% owned subsidiary) was formed as a pharmaceutical distributor with the specific intention of bidding on South African government health care contracts and tenders - in particular; HIV/AIDS medications, and also other health related government tenders including medical equipment, TB drugs and other medical supplies that are either unavailable in South Africa, or too expensive for the government to source from local producers. In addition, Moxisign intends to broaden its governmental and private sector customer base. This expanded reach may add to the scale and flexibility to the Moxisign business model to help it grow substantially within the next five years.

• Moxisign intends to be a pharmaceutical distributor. One aspect of Vantage's business case is Moxisign's ability to import into South Africa, medications and treatments competitively priced and based on the partnerships, technology and skills transfer these partners provide. Moxisign has signed, executed supply agreements with the following entities that covers the pharmaceutical space in which Moxisign intends to compete:

  
  INDIA:

  Amol Pharmaceuticals

  Asence Pharm Ltd

  Swiss Pharma

  CHINA:

  China National Pharmaceutical Group (SINOPHARM)

  GWK Biotechnology Company

  Kehua Bioengineering

• VNTH currently in process of compiling and registering dossiers for various generic molecules within the SADC region. VNTH has successfully registered a herbal anti oxidant and expect to commence sales of this molecule within this quarter. VNTH in process of negotiating further supply agreements. VNTH signed a MOU with Asence Pharma to distribute their products in Southern Africa.

• VNTH through a South African subsidiary to be formed, Vantage Health South Africa, is targeting the private sector in South Africa. Vantage Health's South African subsidiary, Moxisign (Pty) Ltd., is in the final stages of entering into a contract with a health and beauty focused retail, distribution and supply group with over 590 stores across southern Africa. This contact is expected to generate approximately $1,000,000 in gross revenues for that entity. VNTH has approached a national pharmacy chain to supply them with over-the-counter treatments and medications.

• VNTH’s subsidiary Moxisign is currently commencing sales of a recently approved herbal antioxidant. A pipeline of other generics is in process of registration.

• VNTH is in the process of forming a second South Africa subsidiary which will be called Vantage Health South Africa, formed specifically to execute the third phase of the Vantage Health business plan. Phase 3 is the planning, building, commissioning and operation of a pharmaceutical manufacturing facility.

  The manufacturing sector has been targeted by the South African government and is identified as a key pillar in the recent State of the nation address and in the 2010-2013 Industrial Policy Action Plan II and there are, at present, a number of taxation and financial incentives, including grants from the state available to encourage a vibrant manufacturing sector.

  The pharmaceutical partnerships established have agreed to provide VNTH with the requisite technology and skills transfer to establish the plant. At present, VNTH is conducting preliminary feasibility assessment towards the building of the API / secondary formulation plant within South Africa.

  South Africa purchases 70% of the global anti-retroviral market alone and, at this time, does not contribute significantly to producing or supplying products for the marketplace. VNTH sees a gap in the local pharmaceutical manufacturing space that, with the consequent development of employment and associated business in the pharmaceutical, logistics and retail sectors will provide widespread benefits to Africa.

• South Africa has some of the highest rates of HIV and TB in the world: 17.8% of adults aged 15 to 49 are infected with HIV and 73% of them are coinfected with TB. Populations most affected by HIV are women aged 25-29, men aged 30-34, and pregnant women. Those affected by TB live in crowded conditions and have HIV and other comorbidities. Risk factors for HIV are unprotected sex, mother to child transmission, several concurrent sexual relationships, and lack of access to health care. Risk factors for TB are being HIV-positive and immune compromised and living with people that have TB. HIV and TB reduce economic productivity and burden families with the loss of relatives. Interventions for reducing HIV in South Africa are early testing, antiretroviral therapy for HIV positive mothers, better access to contraceptive services, male circumcision, and task shifting of health workers. TB interventions include DOTS management, ARV therapy for HIV positive individuals, and improved air ventilation in hospitals.

  Nature and Magnitude of Problem:

  The prevalence rate of HIV in South Africa is 17.8% for adults age 15 to 49 and approximately 73% of them are coinfected with TB. In the whole population, the incidence rate for HIV was 1.3% in 2008. There are 5,600,000 people living with HIV in South Africa, the highest number of infected individuals globally. Although South Africa only has 0.7% of the world’s population, it has 17% of all HIV cases. Approximately 310,000 people died from HIV in 2009 and 1,900,000 children were left orphaned.

  Tuberculosis is also a major factor in the poor health status of South Africans, and it has become the leading cause of death in South Africa. The number of people diagnosed with TB has increased from about 109,000 cases in 1996 to 400,000 cases in 2007. There were 460,600 new TB cases and 111,924 deaths due to TB in 2009. Over 120,000 people with TB are HIV positive. Overall, South Africa has 24% of all HIV-positive TB cases in the world.

For additional info visit Vantage Health at: http://www.vantagehealthgroup.com

For VNTH stock quote visit: http://www.otcmarkets.com/stock/VNTH/quote